Nick Botwood, M.B.B.S.

Nick Botwood, M.B.B.S.

Head of Research & Development, Chief Medical OfficeratSyndax Pharmaceuticals· In the 2025 proxy

Pay in FY2025Syndax Pharmaceuticals stock +58.9% the same year

Nick Botwood, M.B.B.S. was paid $2.9M in FY2025 (Dec). Syndax Pharmaceuticals stock rose 58.9% that year.

Pay$100 in the stock at the end of FY24 → $159
Pay is from the Summary Compensation Table of each Syndax Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Syndax PharmaceuticalsPublic company · 1 yr
    • Head of Research & Development, Chief Medical Officer2025 – Present · 1 yrStock in role +10%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?